Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Junshi Biosciences

Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Collaboration with Dr. Reddy’s to Develop and Commercialize Toripalimab in 21 Countries
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients
From Junshi Biosciences
Via GlobeNewswire
Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates
From Junshi Biosciences
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.